Cathelicidin-PY
Cathelicidin-PY is an antimicrobial peptide exhibiting strong antimicrobial property. Cathelicidin-PY inhibits the activation of TLR4 inflammatory response pathways induced by lipopolysaccharide (LPS) (HY-D1056). Cathelicidin-PY possesses strong antimicrobial and anti-inflammatory activities and low cytotoxic ability against RAW 264.7 cells. Cathelicidin-PY can be used for antimicrobial and anti-inflammatory research.
For research use only. We do not sell to patients.
- CAS No.: 1431866-92-0
- Formula: C151H263N47O39S2
- Molecular Weight:3425.13
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Cathelicidin-PY exerts strong antimicrobial abilities against most of the tested microorganisms with MIC ranging from 4.69-37.5 μg/mL, and shows same antimicrobial activity against both clinically isolated drug-resistant and standard strains[1].
Cathelicidin-PY (2.5-20 μg/mL, 24 h) exerts anti-inflammatory activitiy by inhibiting the production of nitric oxide (NO) and inflammatory cytokines such as TNF-α, IL-6, and monocyte chemoattractant protein-1 (MCP-1)[1].
Cathelicidin-PY (5-20 μg/mL, 1 h) inhibits the LPS-induced TLR4 signaling pathway in RAW 264.7 murine macrophage cells by downregulating TLR4 expression, inhibiting JNK activation, and preventing NF-κB p65 nuclear translocation in a dose-dependent manner[1].
Cathelicidin-PY (1xMIC, 30 min) induces perturbation of the E. coli cell membrane, as evidenced by membrane breaks, outflow of cellular inclusions, and a vague cell boundary[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 murine macrophage cells
-
Concentration:0, 5, 10, and 20 μg/mL
-
Incubation Time:1 h
-
Result:Inhibited the expression of TLR4, JNK, and the translocation of NF-κB from cytoplasm to nucleus in a dose-dependent manner.
Inhibited 85% TLR4 expression and 74% NF-κB translocation induced by LPS (100 ng/mL, 3 h) at the concentration of 20 μg/mL, respectively.
Inhibited JNK expression induced by LPS.
Completely blocked LPS-induced JNK2 expression at 10 or 20 μg/mL.
Chemical Information
-
CAS No. 1431866-92-0
-
Molecular Weight 3425.13
-
Formula C151H263N47O39S2
-
Sequence
Arg-Lys-Cys-Asn-Phe-Leu-Cys-Lys-Leu-Lys-Glu-Lys-Leu-Arg-Thr-Val-Ile-Thr-Ser-His-Ile-Asp-Lys-Val-Leu-Arg-Pro-Gln-Gly
-
Sequence Shortening
RKCNFLCKLKEKLRTVITSHIDKVLRPQG
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)